RaQualia Pharma's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 179.93.
RaQualia Pharma's Days Inventory for the
three
months ended in Mar. 2026 was 81.
RaQualia Pharma's Days Payable for the
three
months ended in Mar. 2026 was 34.17.
Therefore, RaQualia Pharma's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 226.76.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
RaQualia Pharma Cash Conversion Cycle Related Terms
RaQualia Pharma Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for RaQualia Pharma's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4579 vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, RaQualia Pharma's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
RaQualia Pharma's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaQualia Pharma (TSE:4579) has a Cash Conversion Cycle of 226.76 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on RaQualia Pharma and its competitors.
Is RaQualia Pharma's Cash Conversion Cycle too high?
RaQualia Pharma's current Cash Conversion Cycle is 226.76. The Biotechnology industry median Cash Conversion Cycle is 104.37. RaQualia Pharma's value of 226.76 is 117.3% above this industry median. Overall, RaQualia Pharma has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Cash Conversion Cycle compare to VRTX and REGN?
RaQualia Pharma's Cash Conversion Cycle of 226.76 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 104.37. RaQualia Pharma's value of 226.76 is 117.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 104.37, based on 865 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaQualia Pharma's current Cash Conversion Cycle of 226.76 is 117.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on RaQualia Pharma and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 104.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaQualia Pharma's current Cash Conversion Cycle is 226.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円961.31, compared to a current price of 円468.00 — trading 51.3% below its estimated fair value. The current Cash Conversion Cycle is 226.76 and 117.3% above the Biotechnology industry median of 104.37. RaQualia Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Cash Conversion Cycle is 226.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued.
The current stock price of 円468.00 is trading 51.3% below its estimated GF Value™ of 円961.31.
GuruFocus considers RaQualia Pharma to be Significantly Undervalued.
Key valuation signals for TSE:4579:
Cash Conversion Cycle: 226.76
GF Value™: 円961.31 vs. price of 円468.00 (51.3% below fair value)
Industry Position: 117.3% above the Biotechnology median
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
57GF Score
Get the complete analysis for TSE:4579
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
